Literature DB >> 3579985

Micro-vacuolation in rat brains after long term administration of GABA-transaminase inhibitors. Comparison of effects of ethanolamine-O-sulphate and vigabatrin.

R A John, E M Rimmer, J Williams, G Cole, L J Fowler, A Richens.   

Abstract

Two "suicide" inhibitors of GABA-aminotransferase which are known to raise the concentration of GABA in vivo and to have anti-convulsant properties, have been compared for the extent to which they produce micro-vacuoles in the brains of rats. The compounds gamma-vinyl-GABA (Vigabatrin) and ethanolamine-O-sulphate were administered orally for six months to rats at doses that produced the same increase in brain GABA levels. Micro-vacuolation was found to be present in the brains of animals treated with either compound but to be more severe in those treated with Vigabatrin. A quantitative assessment using computerised image analysis revealed that both the number of vacuoles, and the area occupied by them, was twice as high in the Vigabatrin treated animals as in those treated with ethanolamine-O-sulphate. This quantitative difference could be seen to be due to the fact that in the Vigabatrin treated animals the vacuoles extended into the white matter tracts between the cerebellar folia whereas in those animals treated with ethanolamine-O-sulphate it was confined to the roof nucleus.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3579985     DOI: 10.1016/0006-2952(87)90112-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms.

Authors:  I F Comaish; C Gorman; G M Brimlow; C Barber; G M Orr; N R Galloway
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

2.  Visual field defects associated with vigabatrin therapy.

Authors:  M C Lawden; T Eke; C Degg; G F Harding; J M Wild
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

Review 3.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

4.  In Vivo Detection of CPP-115 Target Engagement in Human Brain.

Authors:  Andrew P Prescot; Steven R Miller; Gary Ingenito; Rebekah S Huber; Douglas G Kondo; Perry F Renshaw
Journal:  Neuropsychopharmacology       Date:  2017-07-25       Impact factor: 7.853

5.  CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms.

Authors:  Stephen W Briggs; Wenzhu Mowrey; Charles B Hall; Aristea S Galanopoulou
Journal:  Epilepsia       Date:  2013-10-28       Impact factor: 5.864

6.  Differential effects of vigabatrin, gamma-acetylenic GABA, aminooxyacetic acid, and valproate on levels of various amino acids in rat brain regions and plasma.

Authors:  W Löscher; D Hörstermann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-03       Impact factor: 3.000

7.  Neurobehavioral effects of vigabatrin and its ability to induce DNA damage in brain cells after acute treatment in rats.

Authors:  Karen Sousa; Natalia Decker; Thienne Rocha Pires; Débora Kuck Mausolff Papke; Vanessa Rodrigues Coelho; Pricila Pflüger; Patrícia Pereira; Jaqueline Nascimento Picada
Journal:  Psychopharmacology (Berl)       Date:  2016-09-27       Impact factor: 4.530

8.  Effects of vigabatrin and of GABA on myelinated rat cerebellar cultures: preliminary data.

Authors:  J J Hauw; J M Boutry; P Sun; V Sazdovitch; C Duyckaerts
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

Review 9.  Prospects for new drug treatment in epilepsy: a review.

Authors:  D Chadwick
Journal:  J R Soc Med       Date:  1990-06       Impact factor: 18.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.